Skip to main content
Clinical Trials/NCT03176316
NCT03176316TerminatedPhase 4

The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus

Loyola University1 site in 1 country53 target enrollmentStarted: September 20, 2017Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Terminated
Sponsor
Enrollment
53
Locations
1
Primary Endpoint
Time to First Bowel Movement

Study Overview

Brief Summary

Postoperative ileus and opioid induced constipation are well-known post-operative complications. Previously, research has shown that using peripherally acting opioid antagonists can help alleviate the condition. There has not been a prospective study to investigate whether use of peripherally acting opioid antagonists are effective in preventing post-operative ileus in patients having spinal fusion surgeries.

Detailed Description

Post operative ileus is a well-known complication following spinal fusion surgery. There has been some literature to demonstrate the safety and efficacy of oral naloxone to decrease the time to bowel movements after gastrointestinal surgery, to date, there have been no studies within the spine fusion literature to investigate oral naloxone's effects on the time to bowel movements.

The aim of the present study is to use the previously established protocols and doses established in the gastrointestinal literature to see whether oral naloxone can decrease the time to first bowel movements.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients will be included if they are having an in-patient spinal fusion procedure, are 18 years or older, post and post-operative pain control plan includes opioid medications.

Exclusion Criteria

  • Pregnancy, age < 18, nursing, or documented allergy to naloxone

Arms & Interventions

Naloxone

Experimental

1 mg/ml oral solution administered enterally every eight hours for 48 hours

Intervention: Naloxone (Drug)

Outcomes

Primary Outcomes

Time to First Bowel Movement

Time Frame: 1 week

We will monitor the patients' bowel movements and record the time to the first bowel movement in hours

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Loyola University
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials